About Evogene Ltd (NYSE:EVGN)
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.
Industry, Sector and Symbol:
- Sector: Non-Cyclical Consumer Goods & Services
- Industry: Agricultural Biotechnology
- Sub-Industry: N/A
- Symbol: NYSE:EVGN
- CUSIP: N/A
- Web: www.evogene.com/
- Market Cap: $120.49 million
- Outstanding Shares: 25,745,000
- 50 Day Moving Avg: $4.50
- 200 Day Moving Avg: $4.94
- 52 Week Range: $4.22 - $6.40
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.37
- P/E Growth: 0.00
- Annual Revenue: $4.61 million
- Price / Sales: 26.14
- Book Value: $3.08 per share
- Price / Book: 1.52
- EBITDA: ($19,560,000.00)
- Net Margins: -235.47%
- Return on Equity: -18.60%
- Return on Assets: -17.16%
- Current Ratio: 17.05%
- Quick Ratio: 17.04%
- Average Volume: 7,953 shs.
- Beta: 0.61
- Short Ratio: 0.3
Frequently Asked Questions for Evogene Ltd (NYSE:EVGN)
What is Evogene Ltd's stock symbol?
Evogene Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVGN."
How were Evogene Ltd's earnings last quarter?
Evogene Ltd (NYSE:EVGN) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.05. The firm earned $1.18 million during the quarter. Evogene Ltd had a negative return on equity of 18.60% and a negative net margin of 235.47%. View Evogene Ltd's Earnings History.
When will Evogene Ltd make its next earnings announcement?
Who are some of Evogene Ltd's key competitors?
Some companies that are related to Evogene Ltd include Benchmark Holdings PLC (BMK), Castle Brands (ROX), Blue Apron Holdings (APRN), Orchids Paper Products Company (TIS), Finsbury Food Group plc (FIF), Carr's Group PLC (CARR), Wynnstay Group plc (WYN), Anpario PLC (ANP), Swallowfield plc (SWL), Produce Investments Ltd (PIL), Dekeloil Public Ltd (DKL), Zambeef Products Plc (ZAM), Spark Networks (LOV), Reed's (REED), Real Good Food PLC (RGD), AdvancePierre Foods Holdings (APFH), Apollo Education Group (APOL) and Asian Citrus Holdings Limited (ACHL).
Who are Evogene Ltd's key executives?
Evogene Ltd's management team includes the folowing people:
- Martin S. Gerstel, Chairman of the Board
- Ofer Haviv, President, Chief Executive Officer
- Alex Taskar, Chief Financial Officer
- Yuval Ben-Galim, Chief Operating Officer
- Hagai Karchi, Executive Vice President, Chief Technology Officer
- Amos Shachar, Vice President of Project Management
- Lea Slonim Bloom, Director of Administration & Human Resources
- Sarit Firon, Director
- Adina Makover, Director
- Leon Yehuda Recanati, Director
How do I buy Evogene Ltd stock?
Shares of Evogene Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evogene Ltd's stock price today?
MarketBeat Community Rating for Evogene Ltd (NYSE EVGN)MarketBeat's community ratings are surveys of what our community members think about Evogene Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Evogene Ltd stock can currently be purchased for approximately $4.68.
Consensus Ratings for Evogene Ltd (NYSE:EVGN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Evogene Ltd (NYSE:EVGN)
Analysts' Ratings History for Evogene Ltd (NYSE:EVGN)
(Data available from 10/16/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/17/2016||Credit Suisse Group||Lower Price Target||Outperform||$19.00 -> $10.00||N/A|
|11/19/2015||Piper Jaffray Companies||Lower Price Target||Neutral||$12.00 -> $8.00||N/A|
Earnings History for Evogene Ltd (NYSE:EVGN)Earnings History by Quarter for Evogene Ltd (NYSE EVGN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/20/2017|| || || || || || || || |
|8/11/2016||Q2||($0.11)||($0.18)||$5.36 million||$3.82 million||View||Listen|
|5/19/2016||Q1||($0.11)||($0.13)||$2.70 million||$2.00 million||View||Listen|
|3/1/2016||Q415||($0.17)||($0.22)||$3.90 million||$2.46 million||View||N/A|
|11/18/2015||Q315||($0.15)||($0.13)||$3.50 million||$3.31 million||View||Listen|
|8/5/2015||Q215||($0.19)||($0.20)||$4.40 million||$2.66 million||View||N/A|
|5/19/2015||Q115||($0.20)||($0.13)||$3.65 million||$2.70 million||View||Listen|
|11/10/2014||Q314||($0.10)||($0.17)||$4.20 million||$3.16 million||View||N/A|
|8/20/2014||Q214||($0.11)||($0.13)||$4.77 million||$3.85 million||View||N/A|
|5/7/2014||Q1 14||($0.13)||($0.09)||$5.40 million||$3.86 million||View||N/A|
|3/19/2014||Q413||($0.08)||($0.20)||$4.95 million||$4.41 million||View||N/A|
Earnings Estimates for Evogene Ltd (NYSE:EVGN)
Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS
Dividend History for Evogene Ltd (NYSE:EVGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Evogene Ltd (NYSE:EVGN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Evogene Ltd (NYSE:EVGN)
Latest Headlines for Evogene Ltd (NYSE:EVGN)
Evogene Ltd (EVGN) Chart for Monday, October, 16, 2017